What are some of the most popular weight loss products endorsed by celebrities in 2024?

1. What people claimed on the record — the headline claims reporters pulled together

Coverage in 2024 repeatedly claimed that several celebrity‑linked products promise weight loss by mimicking or supporting GLP‑1 pathways. High‑profile reporting named Ozempic (semaglutide) and Mounjaro (tirzepatide) as the prescription drugs most frequently associated with celebrities, and identified Kourtney Kardashian’s Lemme GLP‑1 Daily as a signature celebrity‑branded supplement marketed as an “Ozempic‑style” or “GLP‑1 boosting” non‑prescription option ^{[1] [2] [3]}. Other commercial players and programs offering GLP‑1 access or alternatives — such as Noom, Hims & Hers, The Vitamin Shoppe, Veracity and Codeage — were also named in industry coverage as part of the broader market shift toward GLP‑1‑framed products ^[6]. Reporters emphasized that these claims vary sharply in evidentiary support ^[4].

2. The most visible products: drugs vs. supplements and who talked about them

Mainstream reporting split attention between prescription GLP‑1 drugs—Ozempic, Wegovy, Mounjaro—and celebrity‑marketed supplements that claim GLP‑1‑like benefits. Celebrities publicly linked to prescription use included a range of figures reported in late‑2024 coverage; the pharma drugs were framed as the clinically validated interventions behind many personal anecdotes ^[1]. On the supplement side, Lemme GLP‑1 Daily emerged as the clearest celebrity‑branded example launched in 2024, marketed as plant‑based capsules containing patented extracts and sold by subscription ^{[2] [7]}. Industry pieces also noted wellness companies and retailers expanding GLP‑1 programs or GLP‑1‑framed products to meet consumer demand ^{[6] [7]}. The dichotomy between regulated medications and supplements is central to understanding popularity and visibility.

3. What experts and reporters said about the evidence — a consistent cautionary thread

Multiple outlets documented expert skepticism about the scientific basis for supplement claims that they “work like Ozempic.” Articles highlighted that supplement makers often cite small, ingredient‑level studies—sometimes funded by manufacturers—rather than trials of the finished product, and that technical language can give a false impression of equivalence with prescription GLP‑1 agonists ^{[4] [5] [8]}. Reporting on Lemme GLP‑1 Daily specifically noted limited peer‑reviewed evidence for the combined supplement formulation producing clinically meaningful weight loss and urged medical consultation, contrasting that uncertainty with the established clinical trial data supporting prescription GLP‑1 drugs ^{[5] [9] [3]}. The evidence framing therefore separates clinical validation (prescription drugs) from marketing‑level claims (supplements).

4. Celebrity disclosures versus active endorsements — how coverage framed intent and influence

Journalists distinguished between celebrities who publicly use prescription GLP‑1 medications and those who actively commercialize alternatives. Coverage reported celebrities disclosing personal use of Ozempic or Mounjaro in some cases, which drove public interest and media narratives about accessibility and off‑label use ^[1]. Separately, Kourtney Kardashian’s launch of Lemme GLP‑1 Daily represented a commercial endorsement and product roll‑out tied directly to a celebrity wellness brand; outlets tracked the product’s pricing, subscription model, and ingredient list as part of market reporting ^{[2] [7]}. This distinction matters because personal disclosure often fuels demand, while brand launches create structured revenue streams and advertising incentives that shape product messaging ^{[3] [6]}.

5. Commercial incentives and potential agendas behind the messaging

Reporting signaled clear commercial incentives: supplement firms and celebrity brands benefit from the GLP‑1 boom by branding products as “natural” or “Ozempic‑style,” while telehealth and retail companies profit by offering prescription GLP‑1 programs ^{[6] [7]}. Industry articles flagged that supplement patents, proprietary blends, and subscriptions drive higher margins and recurring revenue, which can explain aggressive marketing language and selective citation of small studies ^{[4] [7]}. Media outlets often noted that experts and consumer advocates view such messaging as potentially misleading because it conflates mechanistic plausibility with proven clinical outcomes; the agenda in play is market capture through credible‑sounding science rather than verified therapeutic equivalence ^{[4] [5]}.

6. Date‑stamped comparison and the practical takeaway for consumers

Throughout September–December 2024 coverage, journalists consistently listed Ozempic and Mounjaro as the prescription drugs dominating celebrity narratives, and repeatedly flagged Lemme GLP‑1 Daily as the most visible celebrity‑branded supplement launched in 2024 ^{[2] [1] [3]}. Reporting from September 12–30, 2024 documents the Lemme launch, pricing, and ingredient claims while contemporaneous pieces in late 2024 emphasize broad celebrity association with prescription GLP‑1s and expert caution about supplements’ limited evidence ^{[3] [5] [4]}. The verified fact pattern is: prescription GLP‑1 drugs have stronger clinical backing and celebrity visibility; celebrity supplements gained prominence in 2024 but lack comparable evidence ^{[4] [9] [7]}.